arrow
T

Toshihiro Misumi

National Cancer Center Hospital East
H指数:20
被引数:2,466

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plain language summary of the J-TAIL-2 study results: a study of Japanese patients with extensive-stage small cell lung cancer that followed their treatment with atezolizumab plus chemotherapy over time

J-TAIL-2研究结果的简明摘要:一项关于日本广泛期小细胞肺癌患者接受阿替利珠单抗联合化疗长期随访的研究

2026-10-010
OA
Anterior tumour location as a risk factor for local recurrence after laparoscopic surgery for stage I ultra-low rectal cancers: exploratory analysis of the Ultimate trial

腹腔镜手术治疗后期超低位直肠癌中肿瘤前部位置作为局部复发风险因素的探索性分析:Ultimate试验

2026-09-300
OAAI
Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-derived external control arms

转移性结直肠癌随机试验中基于ARCAD衍生外部对照臂的总体生存期可重复性

2026-08-220
PRE
Recommendations for generating real-world evidence with regulatory-grade relevance and reliability

关于生成具有监管级相关性和可靠性的真实世界证据的建议

2026-08-200
OA
Mapping the Anatomical Landscape of Colorectal Tumours: Location-Specific Efficacy of Anti-Epidermal Growth Factor Receptor Antibodies: Pooled Analysis of Randomised Trials

绘制结直肠癌解剖景观:抗表皮生长因子受体抗体位置特异性疗效:随机试验的合并分析

2026-06-120
PRE
Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI)

利用液体活检多组学和人工智能(AI)进行分子残留病灶(MRD)与多癌种早期检测(MCED)的临床开发

2026-03-060
OAAI
Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab

阿特珠单抗治疗晚期NSCLC患者外周血T细胞谱及血浆蛋白质组学分析

2026-02-020
OAAI
Targeting Driver Mutations in Lung Cancer with Interstitial Pneumonia: A Nationwide Study in Japan

靶向伴有间质性肺炎的肺癌驱动突变:一项日本全国性研究

2026-01-120
PRE
Transanal drainage tube placement in patients with temporary ileostomy after laparoscopic rectal resection for rectal cancer

经肛门引流管置入在腹腔镜下直肠癌切除术后临时性回肠造口患者中的应用

2026-01-012
PRE
Atezolizumab plus Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2)

阿特珠单抗联合化疗治疗日本临床实践中晚期非小细胞肺癌(J-TAIL-2)

2025-12-010
OAAI
Quality of life after laparoscopic surgery for very low rectal cancer: A sub-analysis of the ultimate trial

腹腔镜超低位直肠癌术后生活质量:Ultimate试验的亚组分析

2025-10-060
OAAI
Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: an ARCAD database study

随着奥沙利铂为基础的化疗联合靶向药物,转移性结直肠癌的生存率随时间推移呈逐年改善:一项ARCAD数据库研究

2025-10-020
OAAI
Prognostic factors and efficacy of postoperative chemotherapy in patients with gastric cancer with positive peritoneal cytology after gastrectomy

预后因素及胃癌根治术后腹腔冲洗液细胞学阳性患者的术后化疗疗效

2025-09-150
OA
HIBRID: histology-based risk-stratification with deep learning and ctDNA in colorectal cancer

HIBRID:基于组织学的结直肠癌风险分层,结合深度学习和ctDNA

2025-08-140
OAAI
Association between baseline white blood cell count and future cardiovascular events in patients with stable coronary artery disease- Sub-analysis of the REAL-CAD trial-

稳定冠状动脉疾病患者基线白细胞计数与未来心血管事件关系的关联性——REAL-CAD试验的亚组分析

2025-06-260
OAAI
Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study

拉姆昔利单抗联合多西他赛对比阿特珠单抗治疗既往接受过治疗的PD-L1低表达或阴性晚期非小细胞肺癌的III期研究:WJOG10317L研究

2025-06-230
PRE
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)

Ramucirumab与erlotinib联合作为携带<i>EGFR</i>外显子21 L858R突变的晚期或复发非小细胞肺癌的一线治疗:一项在日本进行的多中心回顾性观察队列研究(REAL-SPEED)。

2025-06-160
OA